Liberty Health Sciences Teams Up with Solomon Wilcots for AAMPA's Conference on the NFL and Medical Cannabis

May 18, 2018 | By forimmediaterele | Filed in: Press Releases.

Travel & Tourism Industry release:

Broadcaster and former player will deliver a message of need and the importance of education to more than 400 physicians

TORONTO, May 18, 2018 /PRNewswire/ – Liberty Health Sciences Inc. (CSE: LHS) (OTCQX: LHSIF) (“Liberty” or the “Company“) today announced it has teamed up with Emmy Award-winning NFL broadcaster and retired player Solomon Wilcots.  Mr. Wilcots is speaking this afternoon in Miami at the American Medical Marijuana Physicians Association’s (“AAMPA“) conference on “The NFL and Medical Cannabis“. He will deliver a critical message of the need for medical cannabis as a treatment option, and the importance of focusing on physician and public education to further its safe and effective use.

“Education is critical to helping doctors and the patients they treat understand and benefit from medical cannabis,” said George Scorsis, Director and CEO of Liberty. “We aim to set the highest standard in the industry with our focus on education and supporting physicians and patients, as seen by our continued rollout of our Cannabis Education Centers across Florida. We are very excited to work with powerful collaborators such as Solomon, who recognize Liberty’s leadership in the industry and support our mission of education and to provide high-quality, pharmaceutical-grade medical cannabis to Florida’s patients in need.”

Originally from Los Angeles, Wilcots is a broadcaster with SiriusXM and Sky Sports (U.K.) who also leads the Sports-Health Alliance of New York City-based communications firm Russo Partners. He has served as an NFL analyst for CBS Sports and NFL Network, as well as a reporter with ESPN and News Channel 5 in Cincinnati. Wilcots spent six seasons in the NFL as a defensive back with the Cincinnati Bengals, Pittsburgh Steelers and Minnesota Vikings. He was a member of Cincinnati’s Super Bowl XXIII team and has been recognized as one of the top-40 all-time Bengals.

“Medical cannabis represents an important treatment option for professional athletes and members of the general public alike,” Wilcots said. “I have seen firsthand the pain and suffering of teammates who, without the benefits of this treatment would have struggled physically and emotionally. The AAMPA conference brings together doctors, former professional football players and their representatives to address the need that exists and ensure the well-being of those involved. I look forward to doing more to help as an educator at this important intersection of sports and medicine.”

About Liberty Health Sciences Inc.

Liberty Health Sciences Inc. is an investor and operator in the medical cannabis market, capitalizing on new and existing opportunities in U.S. states where medical cannabis is legal.  Liberty’s stringent investment criteria for expansion maximizes returns to shareholders, while focusing on significant near- and mid-term opportunities.  Liberty has an extensive background in highly regulated industries, with expertise in becoming a low-cost producer.  Liberty leverages commercial greenhouse knowledge to deliver high-quality, clean and safe pharmaceutical grade cannabis to patients.

For more information, please visit

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: This press release contains certain forward-looking statements within the meaning of applicable securities laws. Any statements that are contained in this news release that are not statements of historical fact may be deemed to be forward-looking statements. Forward-looking statements are often identified by terms such as “may”, “should”, “anticipate”, “expect”, “believe”, “plan”, “intend” or the negative of these terms and similar expressions. Forward-looking statements in this news release include, but are not limited to, expectations related to the growth of demand and registered patient counts in Florida and the Company’s future expansion and growth strategies. Forward-looking statements necessarily involve known and unknown risks, including, without limitation, risks associated with general economic conditions; adverse industry events; marketing costs; loss of markets; future legislative and regulatory developments involving medical marijuana; inability to access sufficient capital from internal and external sources, and/or inability to access sufficient capital on favorable terms; the medical marijuana industry in the United States generally, income tax and regulatory matters; the ability of Liberty to implement its business strategies; competition; crop failure; currency and interest rate fluctuations and other risks.

Readers are cautioned that the foregoing list is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking statements as there can be no assurance that the plans, intentions or expectations upon which they are placed will occur. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement.

Cision View original content:

SOURCE Liberty Health Sciences Inc.

Click here to read the full release with contact information on PR Newswire. Some releases are not in English.

To post and circulate your own press release on FIR and the eTN Network  please click here 


Comments are closed here.